British Journal of Dermatology最新文献

{"title":"Chaperoning a cure: unexpected role of CD74 in cutaneous T-cell lymphoma.","authors":"Robert Gniadecki","doi":"10.1093/bjd/ljaf040","DOIUrl":"10.1093/bjd/ljaf040","url":null,"abstract":"","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":"792"},"PeriodicalIF":11.0,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143057896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The UK-Irish Atopic eczema Systemic TherApy Register (A-STAR): baseline characteristics of the cohort.","authors":"Elizaveta Gribaleva, Kaitlyn Chan, Carlos Chivardi, David Prieto-Merino, Man Fung Tsoi, Rebecca Carroll, Bolaji Coker, Lilia De la Cruz, Manisha Baden, Paula E Beattie, Sara Brown, Tim Burton, Ross Hearn, John R Ingram, Alan D Irvine, Graham A Johnston, Irene Man, Graham Ogg, Mandy Wan, Richard B Warren, Richard T Woolf, Nick J Reynolds, Andrea Manca, Michael R Ardern-Jones, Carsten Flohr","doi":"10.1093/bjd/ljaf039","DOIUrl":"10.1093/bjd/ljaf039","url":null,"abstract":"","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":"927-930"},"PeriodicalIF":11.0,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143057999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term (68 weeks) administration of nemolizumab in paediatric patients aged 6-12 years with atopic dermatitis with moderate-to-severe pruritus: efficacy and safety data from a phase III study.","authors":"Atsuyuki Igarashi, Toshio Katsunuma, Yuko Nagano, Hiroshi Komazaki","doi":"10.1093/bjd/ljae458","DOIUrl":"10.1093/bjd/ljae458","url":null,"abstract":"<p><strong>Background: </strong>A phase III clinical trial in Japanese children aged 6-12 years with atopic dermatitis (AD) and inadequately controlled moderate-to-severe pruritus found that 16 weeks of nemolizumab treatment [30 mg every 4 weeks (Q4W)] was clinically effective and tolerable, with early improvement in pruritus and associated skin signs and a positive impact on patient quality of life (QoL).</p><p><strong>Objectives: </strong>To report the findings from the long-term extension period of the study, and evaluate the efficacy and safety profiles of nemolizumab when administered concomitantly with topical agents over 68 weeks.</p><p><strong>Methods: </strong>The study included a 16-week randomized placebo-controlled double-blind parallel-group period during which patients received nemolizumab 30 mg or placebo Q4W; those who completed this period could enter a 52-week long-term treatment period during which all patients received nemolizumab Q4W. Efficacy endpoints assessed treatment impact on pruritus, AD signs and QoL. Treatment-emergent adverse events (TEAEs) were tabulated to evaluate long-term safety. The study was registered with the Japan Registry of Clinical Trials (jRCT2080225289).</p><p><strong>Results: </strong>Among the 89 paediatric patients evaluated, efficacy outcome measures showed a tendency toward improvement between weeks 16 and 68, and sustained efficacy during the subsequent follow-up period after treatment cessation. At week 68, among patients who received nemolizumab treatment throughout the study, the mean (SD) change from baseline in the 5-level itch score was -1.8 (0.8), the mean (SD) percentage change from baseline in the Average Pruritus Numerical Rating Scale score was -65.9 (25.0), and the mean (SD) percentage change from baseline in the Eczema Area and Severity Index score was -77.1 (23.1). Data from the Dermatitis Family Impact questionnaire indicated that the burden of housework on family members and parent/caregiver fatigue were reduced and the sleep quality of family members was improved by week 16, with further improvement at week 68. The overall safety profile was similar to that recorded in nemolizumab-treated patients aged ≥ 13 years, with no late-onset TEAEs seen over long-term treatment.</p><p><strong>Conclusions: </strong>These data confirm the safety of long-term nemolizumab for paediatric patients with AD, and demonstrate improvements in pruritus, skin symptoms, and patient and caregiver QoL over 68 weeks of treatment.</p>","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":"837-844"},"PeriodicalIF":11.0,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142749981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genome sequencing reveals novel IKBKG structural variants associated with incontinentia pigmenti.","authors":"Neta Pipko, Rachel Youjin Oh, Aiyana Kaplan, Andrea Shugar, Anna Szuto, Miriam Weinstein, Grace Yoon, Roberto Mendoza-Londono, Elena Pope, Ted Young, Christian R Marshall, Gregory Costain, Irene Lara-Corrales, Yiming Wang","doi":"10.1093/bjd/ljae462","DOIUrl":"10.1093/bjd/ljae462","url":null,"abstract":"","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":"933-935"},"PeriodicalIF":11.0,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142695200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New potency labelling of topical corticosteroids in the UK.","authors":"Celia Moss, Michael Ardern-Jones","doi":"10.1093/bjd/ljaf028","DOIUrl":"10.1093/bjd/ljaf028","url":null,"abstract":"","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":"926-927"},"PeriodicalIF":11.0,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of the ustekinumab biosimilar ABP 654 in patients with moderate-to-severe plaque psoriasis: a randomized double-blinded active-controlled comparative clinical study over 52 weeks.","authors":"Andrew Blauvelt, Kim Papp, Mona Trivedi, Carolina Barragan, Vincent Chow, Daniel T Mytych, Paul Yamauchi, Jeff Crowley, Janet Franklin","doi":"10.1093/bjd/ljae402","DOIUrl":"10.1093/bjd/ljae402","url":null,"abstract":"<p><strong>Background: </strong>ABP 654 is a biosimilar to ustekinumab reference product (RP). ABP 654 has been shown to have an amino acid sequence identical to ustekinumab RP and they are similar in structure, purity and potency, as well as clinical pharmacokinetics and safety in healthy volunteers.</p><p><strong>Objectives: </strong>To compare the efficacy, safety and immunogenicity of ABP 654 and ustekinumab RP in patients with moderate-to-severe plaque psoriasis in a randomized double-blinded active-controlled single-transition comparative clinical study (NCT04607980).</p><p><strong>Methods: </strong>Patients were randomized 1 : 1 to receive ABP 654 or ustekinumab RP at a weight-based dose of 45 mg or 90 mg administered subcutaneously on day 1 (week 0), week 4 and week 16. At week 28, patients with a ≥ 75% improvement in Psoriasis Area and Severity Index (PASI) were re-randomized such that those initially randomized to ABP 654 continued to receive ABP 654 and those initially randomized to ustekinumab RP were re-randomized to either continue on ustekinumab RP or transition to ABP 654. The primary efficacy endpoint was percentage improvement in PASI from baseline to week 12. Secondary endpoints included additional efficacy measurements, as well as an assessment of adverse events and antidrug antibodies.</p><p><strong>Results: </strong>At week 12, the observed mean (SD) percentage improvement in PASI from baseline was 81.9 (19.9) and 81.9 (19.6) for the ABP 654 and ustekinumab RP treatment groups, respectively. The point estimate of the mean difference in percentage PASI improvement from baseline to week 12 between the treatment groups was 0.14 with a two-sided 90% confidence interval (CI) of (-2.6 to 2.9), well within the prespecified similarity margin of (-10 to 10). In addition, throughout the study, secondary efficacy analyses and safety and immunogenicity profiles were similar across the treatment groups.</p><p><strong>Conclusions: </strong>These results indicate that ABP 654 and ustekinumab RP are clinically similar in efficacy, safety and immunogenicity in patients with moderate-to-severe plaque psoriasis. Further, a single transition from ustekinumab RP to ABP 654 at week 28 had no impact on the efficacy, safety or immunogenicity results for the remainder of the 52-week study, supporting a conclusion of no clinically meaningful differences between ABP 654 and ustekinumab RP.</p>","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":"826-836"},"PeriodicalIF":11.0,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142495463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preclinical in vitro and in vivo evidence for targeting CD74 as an effective treatment strategy for cutaneous T-cell lymphomas.","authors":"Mariantonia Costanza, Catello Giordano, Ann-Christin von Brünneck, Jing Zhao, Ahmad Makky, Katharina Vinh, Ivonne Aidee Montes-Mojarro, Florian Reisinger, Stephan Forchhammer, Agnieszka Witalisz-Siepracka, Sophie Edtmayer, Dagmar Stoiber, Gang Yin, David Horst, Anja Fischer, Reiner Siebert, Jan P Nicolay, Menghong Yin, Martin Janz, Falko Fend, Jürgen C Becker, Christian M Schürch, Lukas Kenner, Chalid Assaf, Olaf Merkel, Stephan Mathas","doi":"10.1093/bjd/ljaf001","DOIUrl":"10.1093/bjd/ljaf001","url":null,"abstract":"<p><strong>Background: </strong>Prognosis and quality of life in patients with advanced cutaneous T-cell lymphoma (CTCL), particularly in those with Sézary syndrome (SS) or advanced-stage mycosis fungoides (MF), are poor. Monoclonal antibodies or antibody-drug conjugates (ADCs) have been added into CTCL treatment algorithms, but the spectrum of antibody-targetable cell surface antigens in T-cell non-Hodgkin lymphomas (T-NHLs) is limited.</p><p><strong>Objectives: </strong>To evaluate the expression of the major histocompatibility complex class II chaperone CD74 in common subtypes of CTCL by various methods, and to explore the efficacy of targeting CD74 in CTCL cells with an anti-CD74 ADC in vitro and in vivo.</p><p><strong>Methods: </strong>We comprehensively investigated the expression of CD74 in well-defined CTCL cell lines by polymerase chain reaction, immunoblotting and flow cytometry. More than 140 primary CTCL samples of all common subtypes were analysed by immunohistochemistry, flow cytometry, immunofluorescence and 'co-detection by indexing' (CODEX) multiplexed tissue imaging, as well as by single-cell RNA sequencing (scRNAseq) analyses. DNA methylation of CTCL cell lines was interrogated by the generation of genome-wide methylation profiling. The effect of a maytansinoid-conjugated humanized ADC against CD74 was investigated in CTCL cell lines in vitro, alone or in combination with gemcitabine, and in vivo after xenotransplantation of CTCL cell lines in NOD-scid Il2rgnull mice.</p><p><strong>Results: </strong>We demonstrated that CD74 is widely and robustly expressed in CTCL cells. In addition, CD74 expression in SS and MF was confirmed by scRNAseq data analysis and was correlated in CTCL cell lines with CD74 DNA hypomethylation. CD74 was rapidly internalized in CTCL cells and CD74 targeting by the ADC STRO-001 efficiently killed CTCL-derived cell lines. Finally, targeting of CD74 synergized with conventional chemotherapy in vitro and eradicated murine xenotransplants of CTCL cell lines in vivo.</p><p><strong>Conclusions: </strong>CD74 is expressed in common CTCL subtypes. Targeting CD74 efficiently killed CTCL cells in vitro and in vivo. We therefore suggest the targeting of CD74 to be a highly promising treatment strategy for CTCL.</p>","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":"883-895"},"PeriodicalIF":11.0,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of dupilumab for treatment-resistant Grover disease: a retrospective study.","authors":"Shivkar Amara, Kelly Hawkins, Elena Skaggs, Nilesh Kodali, Elisabeth George, Megan Lau, Joseph Largen, Kristina Navrazhina, Mark Lebwohl, Emma Guttman-Yassky","doi":"10.1093/bjd/ljaf036","DOIUrl":"10.1093/bjd/ljaf036","url":null,"abstract":"","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":"941-943"},"PeriodicalIF":11.0,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143051553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Taxonomic and functional profiling of skin microbiome in psoriasis.","authors":"Hanna Sinkko, Peter Olah, Ying Yang, Guilherme Maia, Mauricio Barrientos-Somarribas, Zoltan Rádai, Kuunsäde Mäenpää, Tatiany Soratto, Alexander Salava, Antti Lauerma, Jonathan Barker, Annamari Ranki, Bernhard Homey, Björn Andersson, Nanna Fyhrquist, Harri Alenius","doi":"10.1093/bjd/ljae471","DOIUrl":"10.1093/bjd/ljae471","url":null,"abstract":"","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":"931-933"},"PeriodicalIF":11.0,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142806097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-reported outcome measures are urgently needed for patients with skin of colour who have atopic dermatitis.","authors":"Laura von Kobyletzki, Åke Svensson","doi":"10.1093/bjd/ljaf043","DOIUrl":"10.1093/bjd/ljaf043","url":null,"abstract":"","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":"790"},"PeriodicalIF":11.0,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143188359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}